Author:
Weng Junyong,Li Shanbao,Zhu Zhonglin,Liu Qi,Zhang Ruoxin,Yang Yufei,Li Xinxiang
Abstract
AbstractChemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the tumor cells, it is difficult to make breakthroughs in traditional strategies. The immune checkpoint blockades (ICB) therapy has made significant progress in the treatment of advanced malignant tumors, and patients who benefit from this therapy may obtain a long-lasting response. Unfortunately, immunotherapy is only effective in a limited number of patients with microsatellite instability—high (MSI-H), and segment initial responders can subsequently develop acquired resistance. From September 4, 2014, the first anti-PD-1/PD-L1 drug Pembrolizumab was approved by the FDA for the second-line treatment of advanced malignant melanoma. Subsequently, it was approved for mCRC second-line treatment in 2017. Immunotherapy has rapidly developed in the past 7 years. The in-depth research of the ICB treatment indicated that the mechanism of colorectal cancer immune-resistance has become gradually clear, and new predictive biomarkers are constantly emerging. Clinical trials examining the effect of immune checkpoints are actively carried out, in order to produce long-lasting effects for mCRC patients. This review summarizes the treatment strategies for mCRC patients, discusses the mechanism and application of ICB in mCRC treatment, outlines the potential markers of the ICB efficacy, lists the key results of the clinical trials, and collects the recent basic research results, in order to provide a theoretical basis and practical direction for immunotherapy strategies.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Reference221 articles.
1. Siegel RL, Miller KD. Cancer statistics. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.
2. The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Rectal Cancer. Version 3.2021, (2021).
3. The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Colon Cancer. Version 2.2021, ( 2021).
4. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, (2016).
5. Chibaudel B, et al. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. CA Cancer J Clin. 2015;7:153–69. https://doi.org/10.1177/1758834015572343.
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献